Janssen Pharmaceutica Nv

Astex Therapeutics Limited

Bristol-myers Squibb Compnay

Diego Fernando Domenico Broggini

Patrick René Angibaud

Wim Vermeulen

Russell Mark Jones

Steven Anna Hostyn

Neelakandha S Mani

Daniel J Pippel

Olivier Alexis Georges Querolle

Patrick Rene Angibaud

Susanne Lochner

Vit Lellek

Adrian Maurer

Lana K Young

Filip Albert C Cuyckens

Filip Albert Celine Cuyckens

Yi Xiao

Bin Zheng

Nicolas Cuniere

Yu Fan

Sergei Kolotuchin

Cyril Ben Haim

Eric M Simmons

Carolyn S Wei

Changxia Yuan

Simon Albert Wagschal

Sebastien Francois Emmanuel Lemaire

Helene France Solange Colombel

Subha Mukherjee

Cyril Ben Haïm

Kostiantyn Chernichenko

Duy Chi Trung Cao

Amarjit Singh

Hélène France Solange Colombel

Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.

Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

The invention relates to pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine, or a pharmaceutically acceptable salt thereof or a solvate thereof; to processes for the preparation of said compositions and to the use of said compositions for the manufacture of a medicament for the prophylaxis of or the treatment, in particular the treatment, of diseases, e.g. cancer.

Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

The invention relates to new quinoxaline, quinoline and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Compounds

Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine

The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Quinoxaline derivatives useful as FGFR kinase modulators

The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.

Process for the preparation of histamine H3 receptor modulators

The invention relates to new quinoxaline derivative compounds of formula (I), to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. 

Growing community of inventors

Zurich, Switzerland

Diego Fernando Domenico Broggini